TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics. This deployment marks the company’s first operational entry into pharmaceutical and laboratory automation, according to a press release. The fulfillment of Phase 1 objectives under a joint development agreement was designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows.
The move addresses a growing challenge in laboratory and pharmaceutical operations: improving efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.
TechForce Robotics is extending its Robotics-as-a-Service (RaaS) platform, previously applied in hospitality, into laboratory automation. A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications. This collaboration aims to enhance the capabilities of the LIM-E robot and potentially accelerate the development of automation solutions for the pharmaceutical industry.
The implications of this deployment are significant for the pharmaceutical and biotechnology sectors. By automating routine logistics, organizations can reduce operational costs and improve productivity. The use of AI-enhanced systems also offers the potential for more precise and consistent workflows, which is critical in GMP-regulated environments. For investors, the news provides insight into TechForce Robotics’ diversification strategy and its potential to capture a share of the growing laboratory automation market. The company’s stock, traded under NGTF, may see increased interest as the technology proves its value in real-world applications.
TechForce Robotics’ expansion into pharma underscores a broader trend of automation crossing industry boundaries. As the technology matures, similar deployments could become more common, driving efficiency gains across the life sciences sector. The company’s newsroom at https://ibn.fm/NGTF provides further updates on the ongoing developments.
